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Existing  pharmacological  treatments  for  bipolar  disorder  (BPD)  and  major  depressive 
disorder (MDD) are often insufficient for many patients. Here we describe a number of 
targets/compounds that clinical and preclinical studies suggest could result in putative 
novel  treatments  for  mood  disorders.  These  include:  (1)  glycogen  synthase  kinase-3 
(GSK-3) and protein kinase C (PKC), (2) the purinergic system, (3) histone deacetylases 
(HDACs), (4) the melatonergic system, (5) the tachykinin neuropeptides system, (6) the 
glutamatergic system, and (7) oxidative stress and bioenergetics. The paper reviews data 
on new compounds that have shown antimanic or antidepressant effects in subjects with 
mood  disorders,  or  similar  effects in  preclinical  animal models. Overall,  an  improved 
understanding  of  the  neurobiological  underpinnings  of  mood  disorders  is  critical  in 
order to develop targeted treatments that are more effective, act more rapidly, and are 
better tolerated than currently available therapies. 
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INTRODUCTION 
Mood  disorders,  such  as  bipolar  disorder  (BPD)  and  major  depressive  disorder  (MDD),  are  severe, 
chronic,  and  disabling  psychiatric  disorders  commonly  associated  with  persistent  subsyndromal 
symptoms  and  frequent  episode  relapses[1].  For  instance,  less  than  one-third  of  patients  with  MDD 
achieve remission after 10–14 weeks of treatment with a standard antidepressant[2]. Similarly, in BPD, 
few treatments have proven to be effective for acute depressive episodes or maintenance treatment[3,4]. 
Except for lithium, all available Food and Drug Administration (FDA)–approved treatments for BPD are 
either anticonvulsant or antipsychotic drugs originally developed to treat other conditions[5]. In addition, 
clinical and genetic studies support the notion that mood disorders are heterogeneous conditions with a 
wide range of clinical features. In this context, not all patients benefit from the same treatment; for 
instance, lower response rates are seen in subjects with rapid cycling, as well as those presenting with a 
greater number of psychiatric comorbidities or suicidality.  Machado-Vieira et al.: New Therapeutic Targets for Mood Disorders  TheScientificWorldJOURNAL (2010) 10, 713–726 
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Treatment  of  mood  disorders  has  typically  focused  on  alleviating  symptoms  and  preventing 
recurrence of episodes, but other clinical aspects, such as cognitive function, residual symptoms, and 
suicidal ideation, are also relevant to the notion of effective treatment[6]. Novel treatments are expected 
to address these clinical challenges, and it is critical to the health of our patients that the next generation 
of treatments for mood disorders be more effective, better tolerated, and act faster than currently available 
treatments[7]. 
Here,  we  describe  studies  that  evaluate  potential  promising  targets  for  the  development  of  new, 
improved treatments for mood disorders. Specifically, we review (1) glycogen synthase kinase-3 (GSK-3) 
and  protein  kinase  C  (PKC),  (2)  the  purinergic  system,  (3)  histone  deacetylase  (HDAC),  (4)  the 
melatonergic system,  (5)  the  tachykinin  neuropeptides  system,  (6)  the  glutamatergic  system,  and  (7) 
oxidative stress and bioenergetics (see Table 1). 
TABLE 1 
New Therapeutic Targets in Mood Disorders: Current Evidence for Antimanic (-Like)/ 
Antidepressant (-Like) Effects and Effects of Standard Antidepressants/Mood Stabilizers at  
these Targets 
System 
Antimanic Effects   Antidepressant 
Effects   Target for 
Antidepressants 
Target for 
Mood 
Stabilizers  Clinical  Preclinical  Clinical  Preclinical 
GSK-3  No  Yes  No  Yes  Yes  Yes 
PKC  Yes  Yes  No  Yes  Yes  Yes 
Purinergic  Yes  Yes  No  Yes  No  Yes 
Histone 
deacetylases 
(HDACs) 
No  No  No  Yes  No  Yes 
Melatonergic  No  No  Yes  Yes  Yes  Yes 
Tachykinin 
neuropeptide 
No  No  Yes  Yes  Yes  Yes 
Glutamatergic  No  Yes  Yes  Yes  Yes  Yes 
Oxidative stress 
and 
bioenergetics 
No  No  Yes  Yes  Yes  Yes 
GSK-3, glycogen synthase kinase 3; PKC, protein kinase C. 
This paper reviews data on new compounds that have shown antimanic or antidepressant effects in 
subjects with mood disorders, or similar effects in preclinical animal models. It is important to mention at 
the outset that the extrapolation of animal studies to humans requires cautious interpretation.  
GLYCOGEN SYNTHASE KINASE-3 (GSK-3) AND PROTEIN KINASE C (PKC) 
GSK-3 
GSK-3 is a multifunctional and highly active serine/threonine kinase that regulates diverse signaling 
pathways (e.g., the phosphoinositide 3-kinase [PI3K] pathway, the Wnt pathway, protein kinase A (PKA), 
and PKC). In general, increased activity of GSK-3 is proapoptotic, whereas inhibiting GSK-3 prevents 
apoptosis. GSK-3 (isoforms α and β) is an important regulator of glycogen synthesis, gene transcription, Machado-Vieira et al.: New Therapeutic Targets for Mood Disorders  TheScientificWorldJOURNAL (2010) 10, 713–726 
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synaptic plasticity, apoptosis (cell death), cellular structure, and resilience[8]. It has been suggested that 
GSK-3  regulates  behavior  by  affecting  β-catenin,  glutamate  receptors,  circadian  rhythms,  and 
serotonergic neurotransmission (reviewed in Beaulieu et al.[9]). All of these have been implicated in the 
pathophysiology of severe mood disorders. 
Lithium  has  been  shown  to  target  GSK-3β  in  several  paradigms[9,10,11].  Lithium  also  induces 
neurotrophic and neuroprotective effects in rodents, partly due to GSK-3β inhibition (reviewed in Gould 
and  Manji[12]).  Mice  overexpressing  a  constitutively  active  form  of  brain  GSK-3β  have  increased 
locomotor activity and decreased habituation in the open field test. In contrast, and similar to lithium‟s 
effects,  pharmacologic  or  genetic  inhibition  of  GSK-3β  significantly  decreased  dopamine-dependent 
locomotor hyperactivity and induced similar molecular changes[9,13]. 
In addition, the GSK-3 inhibitor AR-A014418 was shown to have both antidepressant-like effects in 
the forced swim test and antimanic-like effects in the D-amphetamine hyperlocomotion model[14,15]. 
Valproate was initially reported to inhibit GSK-3β activity in SH-SY5Y cells[16,17], but these effects 
have not been confirmed in neuronal cells[18]. With respect to carbamazepine, this drug was reported to 
be  involved  in  signal  transduction  of  cyclic  adenosine  monophosphate  (cAMP)  second  messenger 
systems, but no effect on Akt/GSK-3β has been reported to date[19]. For other agents effective in mood 
disorders,  few  studies  have  been  carried  out  investigating  either  cell  survival  or  potentiation  of  cell 
proliferation, but results suggest that this signaling pathway is not shared by all mood stabilizers[20,21]. 
Taken  together,  these  findings  suggest  that  this  class  of  compounds  has  relevant  antimanic  and 
antidepressant effects. However, inhibition of GSK-3β is associated with some limitations due to its 
involvement  with  diverse  pathways  that  contain  multiple  substrates  that  may  lead  to  side  effects  or 
toxicity[22]. At present, no blood brain barrier–penetrant GSK-selective inhibitors have been clinically 
tested.  Proof-of-principle  studies  with  selective  and  safe  GSK-3β  inhibitors  are  needed  in  order  to 
establish the potential safety and therapeutic relevance of this target in mood disorders. 
PKC Signaling Cascade 
Diverse  studies  support  the  involvement  of  PKC  and  its  substrates  in  the  pathophysiology  and 
therapeutics of BPD[23,24,25,26,27,28]. PKC plays an important role in regulating neuronal excitability, 
neurotransmitter release, and long-term alterations in gene expression and plasticity. Its isoforms differ in 
their  structure,  subcellular  localization,  tissue  specificity,  mode  of  activation,  and  substrate 
specificity[29].  
Diverse studies also show that PKC is regulated by the mood stabilizers lithium and valproate. In 
addition, two recent clinical trials provide further evidence for the involvement of this system in bipolar 
mania[30,31]. Although well known for its antiestrogenic properties, tamoxifen is also a potent PKC 
inhibitor at high concentrations. For instance, one preclinical study found that it decreased amphetamine-
induced  hyperactivity  in  a  large  open field,  a  well-validated  preclinical  measure for  studying  mood-
related  behaviors  compared  with  the  smaller  standard  activity  monitors[32].  In  a  single-blind  study, 
tamoxifen was found to have significant antimanic effects in five of seven BPD subjects[33]. Another 4-
week,  three-arm,  double-blind,  placebo-controlled,  add-on  study  involving  13  women  compared 
tamoxifen (n = 5) to medroxyprogesterone acetate (n = 4) and placebo (n = 4). Subjects in the tamoxifen 
group had a significantly greater decrease in manic and positive psychotic symptoms compared to the 
placebo group. All patients were receiving concomitant treatment that consisted of either lithium (0.8–1.0 
mmol/l)  or  valproate[34].  These  initial  results  were  confirmed  in  two  recent,  3-week,  double-blind, 
placebo-controlled, monotherapy studies[30,31]. The study by Zarate and colleagues tested higher doses 
of up to 140 mg/day and ratings were obtained daily during the first week, thus permitting the assessment 
of early antimanic effects[31]. Yildiz and colleagues used doses of up to 80 mg/day and weekly ratings 
were obtained, but because of the increased sample size, they were able to both separate the effects of 
tamoxifen  on  other  specific  domains  (e.g.,  psychosis  and  depression)  and  to  perform  multivariate 
regression models of response[30]. In all cases, the antimanic effects of tamoxifen were not related to its Machado-Vieira et al.: New Therapeutic Targets for Mood Disorders  TheScientificWorldJOURNAL (2010) 10, 713–726 
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sedative effects, and no increased risk of depression was observed; however, it is possible that some of 
tamoxifen‟s antimanic effects may be due to its antiestrogenic properties (see Goldstein[35]). It is also 
interesting to note that other drugs tested in BPD, such as omega-3 fatty acids and verapamil, inhibit PKC 
activity, which reinforces the role of this target in drug development for BPD. For instance, verapamil had 
significant antimanic effects when combined with lithium in a double-blind, randomized study[36]. There 
is  preliminary  evidence  that  PKC  activation  may  be  a  potential  target  for  developing  novel 
antidepressants[37].  Large  controlled  studies  with  selective  PKC  inhibitors  are  necessary  in  order  to 
confirm the potentially important role of PKC in developing novel therapeutics for mood disorders. 
THE PURINERGIC SYSTEM  
Purinergic  neurotransmission  is  mediated  by  adenosine  triphosphate  (ATP)  and  adenosine,  and  is 
involved  in  regulating  cognition,  sleep,  motor  activity,  appetite,  memory,  and  social  interaction[38]. 
Purines also modulate the activity of diverse neurotransmitters involved in the pathophysiology of mood 
disorders,  such  as  dopamine,  gamma  aminobutyric  acid  (GABA),  and  serotonin[39].  In  preclinical 
paradigms,  adenosine  induced  antidepressant-like  and  anticonvulsant  effects  via  its  effects  at  the 
adenosine 1 and 2A receptors[39,40]. In animal models, adenosine agonists have sedative, anticonvulsant, 
antiaggressive, and antipsychotic properties, while adenosine antagonists (e.g., caffeine) increase anxiety, 
insomnia, and irritability[41,42]. A1 receptor agonists have been shown to limit the activating effects of 
caffeine,  while  A1  receptor  antagonists  induce  stimulating  behavioral  effects  similar  to  those  of 
caffeine[43]. In animal models of mania, the ATP P2 receptor antagonist
 PPADS blocked amphetamine-
induced motor hyperactivity[44].  
Clinically, the involvement of purinergic system dysfunction in mood disorders has been described in 
diverse studies[38,45,46]. Specifically, the purinergic modulator allopurinol showed antimanic efficacy as 
an  add-on  therapy  in  three  different  clinical studies,  one  case report  and two  double-blind,  placebo-
controlled  studies[47,48,49].  Allopurinol  was  significantly  superior  to  placebo  in  decreasing  manic 
symptoms in both controlled studies. Notably, a significant association was found between uric acid 
levels and allopurinol‟s antimanic effects[49]. Recent genetic investigations also suggest that a single 
nucleotide  polymorphism  at  the  P2RX7  gene  may  play  a  role  in  the  pathophysiology  of  mood 
disorders[50,51]. Finally, a recent study found that never-treated subjects with BPD showed increased 
plasma uric acid levels during a first manic episode compared to healthy controls[52]. Further controlled 
studies with allopurinol as monotherapy, as well as the use of more selective purinergic agents, may 
further  clarify  the  role  of  the  purinergic  system  in  the  development  of  new  therapeutics  for  mood 
disorders. 
HISTONE DEACETYLASES (HDACs) 
Epigenetics  involves  the  study  of  heritable  variations  in  gene  function  that  cannot  be  explained  by 
modifications  in  DNA  sequence  and  chromatin  structure[53],  mostly  related  to  decreased  DNA 
methylation and increased acetylation of histones; histones are small proteins that form the nucleosome 
core by complexing with DNA. Epigenetic changes can permanently alter gene expression, which may 
induce  subsequent  changes  in  behavior;  however,  such  effects  may  be  potentially  reversible  over 
time[53]. 
Histone acetylation has been considered a promising therapeutic target in mood disorders because of 
its  ability  to  control  epigenetic  effects  that  regulate
  cognitive  and  behavioral  processes.  Histone 
acetylation reduces histones‟ affinity for DNA and is a major epigenetic regulator of gene expression for 
several key proteins. Thus, diverse HDAC inhibitors have been developed that could serve as novel 
neuroprotective agents; their ability to affect neuronal function and protection occurs largely through 
epigenetic  mechanisms[54].  In  addition,  it  has  been  suggested  that  central  nervous  system  (CNS)–Machado-Vieira et al.: New Therapeutic Targets for Mood Disorders  TheScientificWorldJOURNAL (2010) 10, 713–726 
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penetrant  HDAC  inhibitors  may  eventually  have  potential  therapeutic  relevance  in  mood  disorders, 
supposedly due to their ability to reverse dysfunctional epigenetic effects associated with early life events. 
In  neuronal
  tissue,  HDAC  inhibitors  limit  histone  deacetylation  mostly  by  inactivating  class  I  or  II 
HDACs, thus increasing histone acetylation (for a review see Grayson et al.[55]). 
In animal models of stress and depression, central infusion of an HDAC inhibitor removed the group 
differences in histone deacetylation, DNA methylation, and hypothalamic-pituitary-adrenal (HPA) stress 
responses[56]. Two other preclinical studies[57,58] described antidepressant-like effects associated with 
sodium butyrate, a nonspecific class I and II HDAC inhibitor. Recently, the use of two HDAC inhibitors 
(two selective inhibitors of class I and  II
  HDACs)  administered
  directly into the nucleus accumbens 
induced potent antidepressant-like
 effects in several behavioral models; furthermore, these effects were 
seen at the gene expression level[59]. The same study found a similar decrease in HDAC II protein 
expression in the nucleus accumbens of individuals with MDD.   
Notably, the mood stabilizer valproate is an HDAC inhibitor, suggesting that its effects at this target 
may play a therapeutic role in mood stabilization, although it may also be associated with side effects 
such  as  teratogenicity  or  polycystic  ovarian  syndrome[60,61].  Also,  down-regulation  of  reelin  and 
GAD(67) expression in cortical interneurons in individuals with BPD may be regulated by epigenetic 
hypermethylation[62]. The same group noted that valproate blocked methionine-induced reelin promoter 
hypermethylation and reelin mRNA down-regulation, thus also improving social interaction in preclinical 
models[62].  
Overall,  the  growing  relevance  of  gene-environment  interactions  and  early  life  stressors  in  the 
pathophysiology  of  severe  mood  disorders  raises  the  intriguing  possibility  that  regulating  histone 
acetylation and the clinical use of HDAC inhibitors might represent a new and promising therapeutic 
target in the treatment of mood disorders.    
THE MELATONERGIC SYSTEM 
Melatonin receptors (MT1 and MT2) are highly expressed in the brain, and induce biological effects 
mostly  through  G  protein–coupled  receptors.  Supersensitivity  to  melatonin  suppression  by  light  was 
described  in  individuals  with  mood  disorders  and  their  unaffected  offspring[63].  In  addition,  an 
association  was  described  between  a  polymorphism  in  GPR50  (a  melatonin-related  receptor)  and 
increased risk for BPD[64].  
No controlled studies have evaluated the use of melatonin as a potential treatment for BPD, and case 
reports describe conflicting findings[65,66]. A recent, open-label, 6-week study in 21 individuals with 
BPD assessed the effects of agomelatine (25 mg/day), a nonselective MT1 and MT2 receptor agonist. 
Eighty-one percent of patients achieved significant improvement at end point, and 47% showed response 
during the first week of treatment[67].   
In contrast, strong evidence exists that melatonergic modulators may play a key role as therapeutics 
for MDD. In three large, controlled, multicenter, clinical trials, agomelatine was found to be safe as well 
as more effective than placebo[68,69,70]; agomelatine was also associated with low rates of weight gain 
and sexual dysfunction, and no evidence of discontinuation syndrome[71]. 
In preclinical models, agomelatine had significant antidepressant-like effects in the forced swim test, 
the chronic mild stress test, and the learned helplessness paradigm[72,73,74]. It was also  capable of 
resynchronizing a disrupted circadian rhythm and had circadian phase-advancement properties[75,76,77]. 
Agomelatine  is  also  known  to  increase  both  norepinephrine  and  dopamine,  and  to  increase  cell 
proliferation and neurogenesis in the ventral dentate gyrus[66,78]. Thus, a growing body of evidence 
supports  a  relevant  role  for  melatonergic  modulators  as  therapeutics  for  MDD.  These  findings  are 
promising, and further placebo-controlled studies evaluating their potential use in bipolar depression are 
necessary.  Machado-Vieira et al.: New Therapeutic Targets for Mood Disorders  TheScientificWorldJOURNAL (2010) 10, 713–726 
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THE TACHYKININ NEUROPEPTIDES SYSTEM  
Several preclinical and clinical studies have investigated the potential therapeutic role of the tachykinin 
neuropeptides  system  in  mood  disorders.  These  neuropeptides  involve  substance  P,  neurokinin  A, 
neurokinin B, and their respective receptors (NK1, NK2, NK3). They are G protein–coupled receptors, 
leading  to  activation  of  the  phospholipase  C  (PLC),  inositol  trisphosphate  (IP3),  and  diacylglycerol 
(DAG) signaling cascades[79]. These act as neuromodulators and neurotransmitters, and interact directly 
with  the  monoaminergic  system  in  diverse  brain  areas  implicated  in  mood  regulation  and  emotion-
processing[80].  
Heterogeneous results  were  obtained in  phase  II  and  III  clinical  trials testing  diverse  neurokinin 
receptor antagonists in mood disorders. Three different NK1 receptor antagonists, MK869, L759274, and 
CP122721, reduced depressive symptoms compared to placebo in randomized, double-blind, phase II 
clinical  trials;  both  MK869  and  CP122721  were  associated  with  fewer  side  effects  than  the  active 
comparator (paroxetine or fluoxetine)[81,82]. However, the efficacy of MK869 was not subsequently 
replicated in a multisite, placebo-controlled, phase III trial[83]. Similarly, the NK3 receptor antagonist 
SR142801 (osanetant) was not superior to placebo or paroxetine in a 6-week phase II trial[84]. The most 
promising agent for the treatment of mood disorders appears to be the NK2 receptor antagonist SR48968 
(saredutant), which showed significant antidepressant effects in MDD and is currently in phase III trials. 
The efficacy, tolerability, and safety of this compound were evaluated in adult and elderly patients with 
MDD[80].   
Tachykinin antagonists also induce antidepressant-like effects in preclinical models, particularly NK2 
receptor antagonists[85,86,87,88]. Neurobiological findings further suggest that individuals with MDD 
have increased CSF and serum substance P[80]. Finally, some agents acting as neuropeptide system 
antagonists appear to potentiate the therapeutic effects of selective serotonin reuptake inhibitors (SSRIs). 
Future studies may shed light on the potential role of this system in the therapeutics of mood disorders, 
particularly NK1 and NK2 antagonists. 
THE GLUTAMATERGIC SYSTEM  
Recent research into the etiology of BPD suggests that altered glutamatergic activity involving a potential 
dysregulation in neuroplasticity and cellular resilience may play a key role in this disorder. Therefore, 
diverse glutamatergic modulators that target both ionotropic and metabotropic glutamate receptors have 
been tested in „„proof of concept‟‟ studies in mood disorders[89].  
Ionotropic Glutamate Receptors 
In  preclinical  studies,  N-methyl-D-aspartate  (NMDA)  receptor  antagonists  have  been  found  to  have 
antidepressant-like  effects  (reviewed  in  Zarate  et  al.[90,91]).  For  instance,  the  NMDA  antagonists 
dizocilpine (MK-801) and CGP 37849 exert significant antidepressant-like effects alone or combined 
with standard antidepressants[74,92,93,94,95]. 
Ketamine is a high-affinity NMDA receptor antagonist with a specific type of channel closure (called 
“trapping block”). Ketamine induces  a significant presynaptic release of glutamate by enhancing the 
firing of glutamatergic neurons[96], and it has been proposed that ketamine‟s rapid antidepressant effects 
(described  below)  are  mediated  by  α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate  (AMPA) 
throughput[97].  In  preclinical  models,  ketamine  induced  both  anxiolytic  and  antidepressant 
effects[97,98,99,100,101].  
Ketamine has also been tested in clinical studies. A pilot study found improvement of depressive 
symptoms  72  h  after  ketamine  infusion  in  treatment-resistant  MDD  patients[102].  More  recently,  a 
double-blind, placebo-controlled, cross-over study found that a single ketamine infusion (single-dose, 0.5 Machado-Vieira et al.: New Therapeutic Targets for Mood Disorders  TheScientificWorldJOURNAL (2010) 10, 713–726 
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mg/kg  for  40  min)  in  patients  with  treatment-resistant  MDD  was  associated  with  fast  (within  2  h), 
significant, and relatively sustained antidepressant effects (lasting 1–2 weeks)[103]. More than 70% of 
patients met criteria for response (50% improvement) at 24 h after infusion, and 35% showed a sustained 
response  after  1  week.  Another  selective  NMDA  antagonist,  memantine,  showed  no  antidepressant 
efficacy in a double-blind, placebo-controlled, 8-week trial in 32 subjects with MDD. Trials assessing the 
potential usefulness of more selective subtype NMDA antagonists are under way. 
AMPA  receptor  potentiators  (also  known  as  AMPAkines)  have  also  been  tested  (reviewed  in 
Black[104],  Du  et  al.[105],  and  Miu  et  al.[106]).  In  one  preclinical  study,  the  AMPAkine  Ampalex 
induced  antidepressant-like  effects during  the first days  of  treatment[107].  Such  effects  may  involve 
AMPA receptor trafficking (including receptor insertion, internalization, and delivery to synaptic sites), 
which critically regulates synaptic strength, as well as neural and behavioral plasticity[108].  
Riluzole is FDA approved for the treatment of amyotrophic lateral sclerosis (ALS) based on its well-
characterized neuroprotective properties. Riluzole activates AMPA trafficking and membrane insertion of 
GluR1 and GluR2 subunits, thus limiting glutamate release. Riluzole also enhances glutamate reuptake 
and  activates  synthesis  of  neurotrophins[109,110].  Interestingly,  one  preclinical  study  found  that 
pretreatment  with  10  mg/kg  riluzole  (but  not  3  mg/kg)  moderately  reduced  amphetamine-induced 
hyperlocomotion[111], which could suggest potential antimanic efficacy.  
Clinical studies assessing riluzole‟s efficacy in treating both MDD and BPD have noted that riluzole 
induced significant antidepressant effects and was well tolerated. In one open-label study, 13 patients 
(68%) with MDD completed the trial and all had achieved improvement at week 6[112]. Another open-
label study of 14 patients with BPD found that riluzole (100–200 mg/day) used adjunctively to lithium for 
6 weeks was similarly effective[113]. Another study of 10 patients with treatment-resistant depression 
found  that  riluzole  (50  mg  twice  daily)  added  to  the  patients‟  existing  medications  produced 
antidepressant  effects  after  1  week  of  treatment,  with  a  significant  decrease  (36%)  in  Hamilton 
Depression Rating Scale (HAM-D) scores among completers[114]. Placebo-controlled trials with riluzole 
are needed to confirm these promising findings. Recent data suggest that GluR6 knock-out mice have 
increased motor activity in response to amphetamine challenge, with elevated risk taking and aggressive 
behavior; these manifestations were abolished after chronic treatment with lithium[115]. 
Metabotropic Glutamate Receptors (mGluRs) and Glutamate-Glutamine Cycling 
The mGluR family comprises eight receptor subtypes (mGluR1 to GluR8) classified into three groups 
based on their sequence homology, agonist selectivity, and second messenger systems coupled receptor. 
In several animal models, diverse group I mGluR1 and mGluR5 antagonists induced mood-improving 
effects[89]. For instance, the potent and selective mGluR5 antagonist fenobam induced anxiolytic effects, 
although studies evaluating its use were discontinued because of its psychostimulant effects[116]. In 
addition, the mGluR5-positive allosteric modulator CDPPB reversed amphetamine-induced locomotor 
activity in rodents, with relevance for developing therapeutics for bipolar mania[117].   
The group II mGluR2 and mGluR2/3 receptors reduce excessive glutamate levels into the synapse. 
Diverse  group  II  mGluR  modulators  (e.g.,  LY341495)  have  been  tested  and show  a  dose-dependent 
antidepressant-like efficacy in animal models (reviewed in Zarate et al.[91]). Similarly, group III mGluR 
agonists showed mood-enhancing effects in the forced swim and behavioral despair tests[116,118]. In 
addition,  in  animal  models  of  depression,  mGluR7  knock-out  mice  displayed  an  antidepressant 
phenotype[119]. 
Cytidine is a pyrimidine component of RNA that controls neuronal-glial glutamate cycling, affecting 
cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function. Cytidine was 
studied  as  an  add-on  to  valproate  in  a  double-blind,  12-week,  placebo-controlled  trial  evaluating  35 
individuals with BPD[120]. This agent induced earlier improvement of depressive symptoms in the active 
compound  group,  and  this  improvement  directly  correlated  with  a  decrease  in  midfrontal Machado-Vieira et al.: New Therapeutic Targets for Mood Disorders  TheScientificWorldJOURNAL (2010) 10, 713–726 
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glutamate/glutamine levels. The study suggests that cytidine supplementation has therapeutic effects in 
BPD, potentially mediated by a decrease of cerebral glutamate/glutamine levels.  
OXIDATIVE STRESS AND BIOENERGETICS 
N-Acetyl Cysteine (NAC) 
Increasing evidence suggests that oxidative stress parameters play a key role in the pathophysiology of 
BPD[121,122]. Altered levels of glutathione, the most abundant antioxidant substrate in all tissues, have 
been described in BPD subjects[123,124]. Glutathione production is regulated by its precursor, cysteine. 
Treatment with N-acetyl cysteine (NAC), another precursor of glutathione, increases glutathione levels. A 
recent, randomized, double-blind, multicenter, placebo-controlled study involving 75 patients with BPD 
evaluated NAC (1 g twice daily) added on to treatment as usual over 24 weeks, followed by a 4-week 
washout phase. By study end point, NAC showed superior antidepressant effects compared to placebo, as 
assessed by Montgomery Asberg Depression Rating Scale (MADRS) scores and most secondary scale 
scores[125].  It  is  interesting  to  note  that  patients  were  not  necessarily  selected  for  having  a  major 
depressive episode. However, there was a considerable lag in the benefits obtained, and benefits were lost 
shortly after discontinuing the study medication. No significant differences in side effects compared to 
placebo were noted. The authors hypothesized that NAC‟s efficacy might be due to its ability to reverse 
increased oxidative stress during mood episodes. 
Creatine 
Creatine plays a key role in brain energy homeostasis, and its dysfunction has been implicated in BPD. 
Brain creatine kinase has been shown to be altered in the hippocampus in animal models of mania as well 
as in subjects with BPD during a manic episode[126,127]. Thus, creatine supplementation may modify 
brain high-energy phosphate metabolism in individuals with BPD. Recently, an open-label study in 10 
treatment-resistant patients with depression (two of whom had BPD) found that 3–5 mg/day of creatine 
monohydrate added to ongoing treatment led to a significant improvement in depressive symptoms for 
those  patients  with  MDD[128].  However,  the  two  subjects  with  BPD  experienced  transient 
hypomanic/manic  symptoms.  Further  studies  are  necessary  to  clarify  the  role  of  creatine  in  the 
mitochondrially mediated pathophysiology of BPD[129].  
FINAL REMARKS 
Here we have described potentially promising targets for the development of new, improved treatments 
for mood disorders. Many recent studies have investigated diverse targets/compounds in both animal 
models and at the proof-of-concept stage. These include: (1) glycogen synthase kinase-3 (GSK-3) and 
protein  kinase  C  (PKC),  (2)  the  purinergic  system,  (3)  histone  deacetylases  (HDACs),  (4)  the 
melatonergic system,  (5)  the  tachykinin  neuropeptides  system,  (6)  the  glutamatergic  system,  and  (7) 
oxidative stress and bioenergetics. Several promising compounds targeting these systems have either 
already  undergone  or  are  currently  undergoing  clinical  trials  in  mood  disorders.  These  include 
glutamatergic modulators, PKC inhibitors, allopurinol, agomelatine, and neurokinin receptor antagonists.  
It is important to note that none of these new treatments are FDA approved for the treatment of mood 
disorders. Also, important differences exist when comparing specific compounds, such as patient cohort 
and  methodological  aspects.  Despite  the  many  recent  advances  in  our  knowledge,  future  studies 
investigating  the  efficacy,  safety,  and  potential  mechanisms  involved  in  faster  antidepressant  and 
antimanic actions targeting these systems are necessary. A better understanding of the neurobiological Machado-Vieira et al.: New Therapeutic Targets for Mood Disorders  TheScientificWorldJOURNAL (2010) 10, 713–726 
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underpinnings  of  BPD,  informed  by  preclinical  and  clinical  research,  is  essential  for  the  future 
development of targeted therapies that are more effective, act more rapidly, and are better tolerated than 
currently available treatments. Such novel and improved therapeutics would have a vast and considerable 
impact on public health worldwide.  
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